The EMEA region is witnessing rapid technological advancements in cell counting methodologies. Automated cell counters, flow cytometers, and image-based cell counting systems are gaining prominence, offering more accurate and efficient solutions. This technological progress is a driving force behind the evolving dynamics of the cell counting market in the region.
The EMEA region achieves significant growth in the biopharmaceutical and biotechnology industry. Such is the growth that has been fueling demand for accurate cell counting techniques in areas such as pharmaceutical development, bioprocessor and research which have acted to drive overall market dynamics.
All over the EMEA and world there is increased emphasis on stem cell research. This focus is fueling the demand for sophisticated cell counting techniques that can precisely measure various types of cells in different research and therapeutic uses, affecting market dynamics positively.
Many funds have been put towards life sciences in the EMEA region, which has helped facilitate innovation and developments of cell counting technologies. The market is growing due to the investments made by research institutions, biotech companies as well as academic laboratories in advanced cell counting solutions.
The EMEA regional cell counting market is widening applications in clinical diagnostics. Cell counting is an important part of diagnostic purposes such as detection and monitoring cancerous cells, immune system assessment or infectious disease circulation. This widening of applications is on the one hand leading to a broadened market.
Automated cell counting systems have been gaining popularity in the EMEA region and is a prominent trend observed. Such systems provide better throughput, replicability and accuracy as compared to manual counting methods. The transition towards automation is transforming laboratory workflows and impacting market dynamics.
The EMEA cell counting market has increasingly started observing collaborations and partnerships among the renowned industry players along with academic institutes. Joint ventures help the market in utilizing resources, exchange knowledge and create new technology based products to count cells that are innovative while sustaining competition.
The rigid regulatory frameworks of pharmaceutical and biotechnology industries have amplified the demand for sturdy cell counting solutions in EMEA region. Adherence to the regulatory compliance and maintaining standards in cell-based research as well as manufacturing processes are key factors that affect market dynamics.
Competition levels prevail in the EMEA cell counting market, with companies having to participate in strategic initiatives like mergers and acquisitions that boost their standing. Such consolidation is shaping the competitive landscape and overall market dynamics.
Ongoing developments in healthcare infrastructure across the EMEA region are contributing to the growth of the cell counting market. The expansion of healthcare facilities and research institutions creates a conducive environment for the adoption of advanced cell counting technologies.
Europe, the Middle East and Africa Cell Counting Market Size was valued at USD 3.83 Billion in 2023. The Europe, the Middle East and Africa Cell Counting industry is projected to grow from USD 4.03 Billion in 2024 to USD 6.03 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.24% during the forecast period (2024 - 2032). Cell counting is used for the quantification of cells in life sciences. Cell counting is important for research and serves as one of the major steps in a majority of experiments. It is effectively utilized for maintaining cell cultures. Moreover, another important application of cell counting can be seen in the diagnosis of chronic diseases like cancer. For instance, increase in the number of white blood cells (WBC) may indicate the possibility of cancerous growth in the body. Thus, cell counting is important for microbiology, hematologic and other medical specialties.
Rising prevalence of chronic diseases like cancer, TB (tuberculosis), AIDS along with increasing healthcare sector is driving the growth of this market. According to the World Health Organization, cancer was the second leading cause of death across the globe in 2015 and caused around 8.8 million deaths globally.
Moreover, it was estimated that more than 70% of the deaths due to cancer was caused in the middle and low-income countries. Moreover, increasing biotechnology industries and growing pharmaceutical sector is fuelling the market growth during the forecast period.
In 2017, according to the Biotechnology and Biological Sciences Research Council (BBSRC), the European industrial biotechnology industry is expected to reach approximately USD 53.2 billion by 2030 from 28 billion in 2013. However, lack of skilled professionals and the high cost of the cell counting equipment may restrain the market growth during the forecast period. The EMEA cell counting market is expected to grow at an approximate CAGR of 8.6% during the forecast period.
The market is segmented into instruments, consumables & accessories, and others. The instrument segment is sub-segmented into spectrophotometers, flow cytometers, hematology analyzers, cell counters, and others. The consumables & accessories segment is sub-segmented into reagents, microplates, and others.
The market is segmented into hematology, microbiology, and others.
The market is segmented into hospitals & clinics, research organizations, academic institutes, and others.
Europe is the largest EMEA cell counting market. Rising government support for research and a well-developed healthcare infrastructure within the region is driving the market growth within the region. This along with a huge patient population and growing healthcare expenditure is fuelling the market growth. According to the Cancer Research UK in 2014, about 356,860 new cases of cancer were reported within the region. Moreover, the total estimated deaths due to the same in 2014 were about 163,444.
Asia Pacific is the fastest growing region in the EMEA cell counting market. Presence of a huge patient population and continuously developing economies like India and China within the region drive the market growth. According to the Indian Brand Equity Foundation in 2017, the Indian healthcare sector is one of the fastest growing industries and is expected to advance at a CAGR of 22.8% and reach USD 280 billion by 2020. Moreover, according to the National Institute of Cancer Prevention and Research in 2017, about 2.5 million people are living with cancer. Additionally, favorable government policies like reduced excise and customs duty followed by the exemptions in service tax boost the market growth. Additionally, increasing healthcare expenditures fuels the market within the region.
On the other hand, the Middle East & Africa holds the least share in the EMEA cell counting market due to the presence of poor economy, especially within the African region. Moreover, the absence of developed healthcare sector and stringent government policies are expected to restrain the market growth within the region. Majority of the market within the region is held by the Middle East due to huge healthcare expenditures and presence of developed economies like Kuwait, Saudi Arabia, Dubai, and Qatar.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)